79 studies found for:    Open Studies | "Mesothelioma"
Show Display Options
Rank Status Study
21 Recruiting Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
Condition: Unresectable Pleural or Peritoneal Malignant Mesothelioma
Interventions: Drug: Tremelimumab;   Drug: Placebo
22 Recruiting Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma
Condition: Advanced Malignant Pleural Mesothelioma
Interventions: Drug: NGR-hTNF;   Drug: Placebo;   Other: Best Supportive Care
23 Unknown  Mesothelin and Osteopontin as Diagnostic Markers in Patients With Mesothelioma or Atypical Mesothelial Hyperplasia
Conditions: Malignant Mesothelioma;   Metastatic Cancer
Interventions: Other: laboratory biomarker analysis;   Procedure: study of high risk factors
24 Recruiting ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)
Condition: Malignant Pleural Mesothelioma
Intervention: Drug: Trabectedin
25 Recruiting Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma.
Condition: Malignant Pleural Mesothelioma
Intervention: Drug: VS-6063
26 Recruiting Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.
Condition: Malignant Pleural Mesothelioma
Intervention: Biological: HSV1716 Intra-pleural delivery
27 Not yet recruiting Thromboelastography During Surgery for Malignant Pleural Mesothelioma
Conditions: Coagulopathy;   Mesothelioma
Intervention: Procedure: Blood draw for TEG analysis
28 Recruiting Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
Conditions: Lung Cancer;   Esophageal Cancer;   Malignant Pleural Mesothelioma;   Sarcoma;   Thymic Carcinoma
Interventions: Biological: Allogeneic Tumor Cell Vaccine (K562);   Drug: Celecoxib;   Drug: cyclophosphamide
29 Unknown  An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma
Condition: Mesothelioma
Intervention: Drug: Milataxel
30 Recruiting A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma
Conditions: Malignant;   Pleural;   Mesothelioma
Interventions: Biological: TroVax®;   Drug: Pemetrexed;   Drug: Cisplatin;   Dietary Supplement: Vitamin B12;   Dietary Supplement: Folic Acid;   Drug: Dexamethasone
31 Recruiting Nintedanib (BIBF 1120) in Mesothelioma
Condition: Mesothelioma
Interventions: Drug: Nintedanib;   Drug: Pemetrexed;   Drug: Cisplatin;   Drug: Placebo
32 Unknown  Cisplatin With Alimta or Gemcitabine in Long Infusion for Mesothelioma
Condition: Mesothelioma
Intervention: Procedure: Gemcitabine in long infusion
33 Not yet recruiting MARS 2: A Feasibility Study Comparing (Extended) Pleurectomy Decortication Versus no Pleurectomy Decortication in Patients With Malignant Pleural Mesothelioma
Condition: Mesothelioma
Intervention: Procedure: (Extended) pleurectomy decortication
34 Recruiting The ISET (Isolation by Size of Epithelial Tumor Cells) and the CellSearch Methods in Malignant Pleural Mesothelioma
Conditions: Pleural Neoplasms;   Mesothelioma;   Pneumothorax;   Parathyroid Neoplasms;   Benign Tumor of the Thyroid;   Tumor of the Thyroid
Interventions: Other: Blood sampling;   Other: Control Group
35 Unknown  A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma
Condition: Mesothelioma
Intervention: Drug: Imatinib mesylate plus Gemcitabine
36 Recruiting Intrapleural Gene Transfer for Pleural Mesothelioma
Condition: Malignant Pleural Mesothelioma
Intervention: Biological: SCH 721015
37 Recruiting Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
Condition: Pleural Mesothelioma
Intervention: Drug: Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)
38 Recruiting Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Condition: Malignant Pleural Mesothelioma
Interventions: Drug: defactinib (VS-6063);   Drug: Placebo
39 Unknown  Trimodality Therapy for Malignant Pleural Mesothelioma
Condition: Malignant Pleural Mesothelioma
Intervention:
40 Recruiting Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma
Condition: Malignant Peritoneal Mesothelioma
Interventions: Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years